Metformin alone and in combination with sitagliptin induces depression and impairs quality of life in type 2 diabetes mellitus patients: An observational study

• Published in: International journal of clinical pharmacology and therapeutics Vol. 61; no. 3; pp. 102 - 110
• Main Authors: Athar, Mohammed, Garg, Aakriti, Khan, Mohd Ashif, Parveen, Rizwana, Kohli, Sunil, Vohora, Divya, Nidhi
• Format: Journal Article
• Language: English
• Published: Germany Dustri - Verlag Dr. Karl Feistle GmbH & Co. KG 01.03.2023
• Subjects: Antidiabetics; Blood Glucose; Cognition & reasoning; Depression - chemically induced; Depression - diagnosis; Diabetes; Diabetes Mellitus, Type 2 - diagnosis; Diabetes Mellitus, Type 2 - drug therapy; Dipeptidyl-Peptidase IV Inhibitors - adverse effects; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents - adverse effects; Metformin - adverse effects; Observational studies; Quality of Life; Sitagliptin Phosphate - adverse effects

Various studies have reported the association of cognition and depression with diabetes. Literature suggests that metformin and sitagliptin used to control hyperglycemia in type 2 diabetes mellitus (T2DM) possess a beneficial effect on neurological symptoms associated with diabetes. However, there a...